FDA released the Center For Drug Evaluation and Research (CDER) Drug Safety Priorities 2017 annual report. The report describes CDER’s work in 2017 to enhance drug safety for the American public, including safety surveillance and oversight of marketed drug products, the importance of real-world evidence to help advance drug safety science, new tools and approaches for fighting the opioid crisis, safety oversight for generic drugs, efforts to reduce preventable harm from medications, compounded drugs – continuing regulatory and oversight efforts, and diverse strategies, tools and services for communicating drug safety. REPORT

The report describes many ways CDER worked in 2017 to enhance drug safety for the American public. These include:

  • Safety surveillance and oversight of marketed drug products
  • The importance of real-world evidence to help advance drug safety science:
  • New tools and new approaches for fighting our Nation’s opioid crisis
  • Safety oversight for generic drugs
  • Efforts to reduce preventable harm from medications
  • Compounded drugs – continuing regulatory and oversight efforts
  • Diverse strategies, tools, and services for communicating drug safety

Source: FDA Voice.